drugset / Trial / NCT02637375
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
Withdrawn
University of Chicago
NaSingle-groupOpen-labelTreatment
Summary
Based on preclinical data implicating GR, AR, and JAK/STAT activation as potent mechanisms of breast cancer cell survival despite chemotherapy administration (i.e. chemotherapy resistance), the study will test a novel approach for improving chemotherapy effectiveness by adding Hsp90 inhibition to antagonize the anti-apoptotic signaling pathways that are initiated via GR, AR, and JAK/STAT activation.
Timeline
- Start
- 2016-05
- Primary completion
- 2018-12
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped: “Study never opened (terminated as study drug no longer available)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Ganetespib | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |